© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
In this interview, Laurence Klotz, MD, discusses his group's active surveillance protocol for men with favorable-risk prostate cancer, which men are candidates, how they are monitored, and triggers for active treatment.
Related Content:
News